Multimorbid pathology at psoriasis (scientific review)

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic auto-inflammatory process in psoriasis is associated with the involvement of internal organs and systems, as well as the development of several systemic disorders: heart failure, psoriatic arthritis, diabetes, obesity, etc. In this regard, the purpose of our study is to integrate information about comorbid and concomitant pathology in patients with psoriasis. Data on the biological aspects of the increased risk of occurrence and adverse cardiovascular outcome of myocardial infarction, stroke and cardiovascular mortality in patients with psoriasis are supported by clinical observations on the relationship of the course of coronary heart disease with the area of skin lesion. The association between the presence of obesity and an increased level of proinflammatory cytokines has been confirmed, which may be one of the triggers for the development of psoriatic arthritis associated with early disability of patients with psoriasis. There was a greater incidence of non-response to psoriasis treatment among obese patients. Cardiovascular complications are the most common cause of death for patients with psoriasis. Identifying common combinations of comorbid and concomitant diseases in the main chronic disease can serve as a basis for the development of tactics and criteria for patient management in order to optimize treatment.

Full Text

Restricted Access

About the authors

Timur Z. Alikbaev

North-Western State Medical University named after I.I. Mechnikov; Saint Petersburg State University, The Pirogov Clinic of High Medical Technologies

Author for correspondence.
Email: talikbaev@mail.ru
ORCID iD: 0000-0003-0937-2540
SPIN-code: 3925-0304

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg; Saint Petersburg

Sergey A. Sayganov

North-Western State Medical University named after I.I. Mechnikov

Email: ssayganov@gmail.com
ORCID iD: 0000-0001-8325-1937
SPIN-code: 2174-6400

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Konstantin I. Raznatovskiy

North-Western State Medical University named after I.I. Mechnikov

Email: konstantan.r@bk.ru
ORCID iD: 0000-0003-1022-7463
SPIN-code: 4587-2393

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

References

  1. Kungurov NV, Filimonkova NN, Tuzankina IA. Psoriasis Vulgaris. Ekaterinburg: Izd-vo Ural’skogo un-ta; 2002. 200 p. (In Russ.)
  2. Sorokina EV, Bisheva IV. The role of cells of the innate immune system in psoriasis. Vestnik dermatologii i venerologii. 2022;98(5):59–64. EDN: OKYHPG doi: 10.25208/vdv1330
  3. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–307. doi: 10.1111/j.1600-0625.2011.01261.x
  4. Mazurov VI, Trofimov EA, Gaidukova IZ. The place of a phosphodiesterase 4 inhibitor in the treatment strategy for psoriatic arthritis. Modern Rheumatology Journal. 2018;12(1):41–46. EDN: XPUTRR doi: 10.14412/1996-7012-2018-1-41-46
  5. Potekaev NN, Zhukova OV, Artem’eva SI. Psoriasis: a personalized approach to therapy. The preferred choice of systemic agents considering comorbid pathologies. Medical Council. 2020;12:28–34. EDN: MCMQOZ doi: 10.21518/2079-701X-2020-12-28-34
  6. Olisova OYu, Garanyan LG. Comorbidities in psoriasis Russian Journal of Skin and Venereal Diseases. 2016;19(6):346–348. EDN: XUWDTR doi: 10.18821/1560-9588-2016-19-6-346-348
  7. Alikbaev TZ, Frolova EV, Gulordava MD, et al. Modern ideas about the pathogenesis, clinic and treatment of severe psoriasis. Problems in Medical Mycology. 2021;23(4):9–16. EDN: STXXRQ doi: 10.24412/1999-6780-2021-4-9-16
  8. Patrick MT, Li Q, Wasikowski R, et al. Shared genetic risk factors and causal association between psoriasis and coronary artery disease. Nat Commun. 2022;13(1):6565. doi: 10.1038/s41467-022-34323-4
  9. Reed WB, Becker SW, Rohde R, Heiskell CL. Psoriasis and arthritis. Clinicopathologic study. Arch Dermatol. 1961;83:541–548. doi: 10.1001/archderm.1961.01580100005001
  10. Mehta NN, Krishnamoorthy P, Yu Y, et al. The impact of psoriasis on 10-year Framingham risk. J Am Acad Dermatol. 2012;67(4):796–798. doi: 10.1016/j.jaad.2012.05.016
  11. Smirnova IO, Vladimirova IS. Psoriasis and cardiovascular comorbidity (literature review). Medical alphabet. 2020;(6):18–21. EDN: QFFIMW doi: 10.33667/2078-5631-2020-6-18-21
  12. Armstrong AW, Guérin A, Sundaram M, et al. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. J Am Acad Dermatol. 2015;72(6):968–977. doi: 10.1016/j.jaad.2015.02.1095
  13. Sofidis G, Stalikas N, Papathemeli D, et al. Correlation of psoriasis severity with angiographic coronary artery disease complexity: a cross-sectional study. J Eur Acad Dermatol Venereol. 2021;35(6):372–373. doi: 10.1111/jdv.17143
  14. Lerman JB, Joshi AA, Chaturvedi A, et al. Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study. Circulation. 2017;136(3):263–276. doi: 10.1161/CIRCULATIONAHA.116.026859
  15. Boehncke W-H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579. doi: 10.3389/fimmu.2018.00579
  16. Mansouri B, Kivelevitch D, Natarajan B, et al. Comparison of coronary artery calcium scores between patients with psoriasis and type 2 diabetes. JAMA Dermatol. 2016;152(11):1244–1253. doi: 10.1001/jamadermatol.2016.2907
  17. Gupta Y, Möller S, Zillikens D, et al. Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease. Exp Dermatol. 2013;22(8):552–553. doi: 10.1111/exd.12192
  18. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. doi: 10.1001/jama.296.14.1735
  19. Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2022;86(1):68–76. doi: 10.1016/j.jaad.2021.06.883
  20. Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: A population-based cohort study in the U.K. Br J Dermatol. 2010;163:586–592. doi: 10.1111/j.1365-2133.2010.09941.x
  21. Goto H, Nakatani E, Yagi H, et al. Late-onset development of psoriasis in Japan: a population-based cohort study. JAAD Int. 2021;2:51–61. doi: 10.1016/j.jdin.2020.10.011
  22. Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71(8):1273–1277. doi: 10.1136/annrheumdis-2012-201299
  23. Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther. 2019;21(1):17. doi: 10.1186/s13075-019-1810-5
  24. Russolillo A, Iervolino S, Peluso R, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford). 2013;52(1):62–67. doi: 10.1093/rheumatology/kes242
  25. Moroni L, Farina N, Dagna L. Obesity and its role in the management of rheumatoid and psoriatic arthritis. Clin Rheumatol. 2020;39(4):1039–1047. doi: 10.1007/s10067-020-04963-2
  26. Llamas-Velasco M, Ovejero-Merino E, Salgado-Boquete L. Obesity — a risk factor for psoriasis and COVID-19. Actas Dermosifiliogr. 2020;112(6):489–494. (In Spanish) doi: 10.1016/j.ad.2020.12.001
  27. Karmacharya P, Ogdie A, Eder L. Psoriatic arthritis and the association with cardiometabolic disease: A narrative review. Ther Adv Musculoskelet Dis. 2021;13:1759720X21998279. doi: 10.1177/1759720X21998279
  28. Castaldo G, Rastrelli L, Galdo G, et al. Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trial. Nutrition. 2020;74:110757. doi: 10.1016/j.nut.2020.110757
  29. Nasonov EL, Korotaeva TV, Lila AM, Kubanov AA. Can the development of psoriatic arthritis be prevented in patients with psoriasis? Rheumatology Science and Practice. 2019;57(3):250–254. EDN: BWOEZJ doi: 10.14412/1995-4484-2019-250-254
  30. Ceccarelli M, Venanzi Rullo E, Berretta M, et al. New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection. Dermatol Ther. 2021;34(1):e14660. doi: 10.1111/dth.14660
  31. Lila AM, Nasonov EL, Korotaeva TV. Psoriatic arthritis: pathogenetic features and innovative therapies. Rheumatology Science and Practice. 2018;56(6):685–691. EDN: MSVMHQ doi: 10.14412/1995-4484-2018-685-691
  32. Mody E, Husni ME, Schur P, Qureshi AA. Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience. Br J Dermatol. 2007;157(5):1050–1051. doi: 10.1111/j.1365-2133.2007.08139.x
  33. Rozumbaeva LP, Kozlova IV, Bykova AP. Comorbidity of diseases of the liver, biliary tract and psoriasis. Experimental and Clinical Gastroenterology. 2015;114(2):24–28. EDN: THKCKL
  34. Bakulev AL. Methotrexate: Revisited efficiency and safety of drug administration in psoriasis patients. Vestnik dermatologii i venerologii. 2017;93(1):38–45. EDN: YGRYAN doi: 10.25208/0042-4609-2017-93-1-38-45
  35. Zhukov AS, Khotko AA, Khairutdinov VR, Samtsov AV. Profiles of patients with psoriasis for appointment gene-engineering biological therapy – clinical justification. Vestnik dermatologii i venerologii. 2020;96(1):58–66. EDN: YMOWXW doi: 10.25208/vdv550-2020-96-1-58-66
  36. Abdulganieva DI, Bakulev AL, Belousova EA, et al. Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy and for use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn’s disease). Modern Rheumatology Journal. 2018;12(3):4–18. EDN: YOCLQT doi: 10.14412/1996-7012-2018-3-4-18
  37. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850. doi: 10.1016/j.jaad.2008.02.039
  38. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–848. doi: 10.1111/bjd.18245

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 71733 от 08.12.2017.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies